Immuneering Advances Pancreatic Cancer Drug with Key ASCO Presentation and Phase 3 Trial Launch
Event summary
- Immuneering to present new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP at the 2026 ASCO Annual Meeting on June 1.
- Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now recruiting, with first patient dosing on track for mid-2026.
- 27 months progression-free survival observed in a third-line pancreatic cancer patient treated with atebimetinib monotherapy, with an 85% reduction in tumor burden.
- Immuneering ended Q1 2026 with $198.6 million in cash, anticipating runway into 2029.
The big picture
Immuneering's progress with atebimetinib underscores the growing focus on targeted therapies for pancreatic cancer, a field with significant unmet needs. The company's strategic shift towards combination therapies and its ability to demonstrate durable survival benefits could position it as a key player in the oncology space. The upcoming ASCO presentation and Phase 3 trial launch are critical milestones that will shape Immuneering's trajectory in the competitive landscape of cancer drug development.
What we're watching
- Clinical Efficacy
- How the upcoming ASCO presentation will impact investor confidence in atebimetinib's potential as a first-line treatment for pancreatic cancer.
- Regulatory Pathway
- Whether the Phase 3 MAPKeeper 301 trial will meet its mid-2026 dosing timeline and its implications for Immuneering's regulatory strategy.
- Financial Sustainability
- The pace at which Immuneering will need to secure additional funding to extend its cash runway beyond 2029.
Related topics